Literature DB >> 30940637

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Ralf Buettner1, Corey Morales1, Enrico Caserta1, Estelle Troadec1, Emine G Gunes1, Domenico Viola1, Jihane Khalife1, Hongzhi Li2, Jonathan J Keats3, Austin Christofferson3, Xiwei Wu4, Timothy W Synold5, Joycelynne Palmer2, James F Sanchez1, Alexander Pozhitkov2, Nagarajan Vaidehi2, Guido Marcucci6, Amrita Krishnan1, Michael A Rosenzweig1, Flavia Pichiorri1, Steven T Rosen1.   

Abstract

Entities:  

Year:  2019        PMID： 30940637      PMCID： PMC6457239          DOI： 10.1182/bloodadvances.2018027227

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  23 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

2.  Addiction to c-MYC in multiple myeloma.

Authors:  Toril Holien; Thea Kristin Våtsveen; Hanne Hella; Anders Waage; Anders Sundan
Journal:  Blood       Date:  2012-07-17       Impact factor: 22.113

3.  Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.

Authors:  Jing Zheng; Yonggang Sha; Logan Roof; Oded Foreman; John Lazarchick; Jagadish Kummetha Venkta; Cleopatra Kozlowski; Cristina Gasparetto; Nelson Chao; Allen Ebens; Jianda Hu; Yubin Kang
Journal:  Cancer Lett       Date:  2018-10-09       Impact factor: 8.679

4.  The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.

Authors:  J P Davis; G A Cain; W J Pitts; R L Magolda; R A Copeland
Journal:  Biochemistry       Date:  1996-01-30       Impact factor: 3.162

Review 5.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.

Authors:  Deepti Mathur; Elias Stratikopoulos; Sait Ozturk; Nicole Steinbach; Sarah Pegno; Sarah Schoenfeld; Raymund Yong; Vundavalli V Murty; John M Asara; Lewis C Cantley; Ramon Parsons
Journal:  Cancer Discov       Date:  2017-03-02       Impact factor: 39.397

7.  Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Authors:  Angela Baker; Esteban Braggio; Susanna Jacobus; Sungwon Jung; Dirk Larson; Terry Therneau; Angela Dispenzieri; Scott A Van Wier; Gregory Ahmann; Joan Levy; Louise Perkins; Seungchan Kim; Kimberly Henderson; David Vesole; S Vincent Rajkumar; Diane F Jelinek; John Carpten; Rafael Fonseca
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

8.  The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.

Authors:  Teresa Paíno; Antonio Garcia-Gomez; Lorena González-Méndez; Laura San-Segundo; Susana Hernández-García; Ana-Alicia López-Iglesias; Esperanza M Algarín; Montserrat Martín-Sánchez; David Corbacho; Carlos Ortiz-de-Solorzano; Luis A Corchete; Norma C Gutiérrez; María-Victoria Maetos; Mercedes Garayoa; Enrique M Ocio
Journal:  Clin Cancer Res       Date:  2016-07-20       Impact factor: 12.531

9.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

Review 10.  Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.

Authors:  Carmen Blanco-Aparicio; Amancio Carnero
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858
View more
  6 in total

1.  Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.

Authors:  Michael Rosenzweig; Joycelynne Palmer; Ni-Chun Tsai; Tim Synold; Xiwei Wu; Shu Tao; Samantha N Hammond; Ralf Buettner; Lupe Duarte; Myo Htut; Chatchada Karanes; Nitya Nathwani; Flavia Pichiorri; Firoozeh Sahebi; James F Sanchez; Arnab Chowdhury; Amrita Krishnan; Stephen J Forman; Steven T Rosen
Journal:  Leuk Lymphoma       Date:  2020-04-08

Review 2.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

3.  Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.

Authors:  Ralf Buettner; Le Xuan Truong Nguyen; Corey Morales; Min-Hsuan Chen; Xiwei Wu; Lisa S Chen; Dinh Hoa Hoang; Servando Hernandez Vargas; Vinod Pullarkat; Varsha Gandhi; Guido Marcucci; Steven T Rosen
Journal:  J Hematol Oncol       Date:  2021-04-26       Impact factor: 17.388

Review 4.  MYC inhibitors in multiple myeloma.

Authors:  Sandra Martínez-Martín; Laura Soucek
Journal:  Cancer Drug Resist       Date:  2021-08-13

Review 5.  Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.

Authors:  Cho-Hsun Hsieh; Yi-Wei Huang; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-05

6.  Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer.

Authors:  Thuy Phan; Vu H Nguyen; Ralf Buettner; Corey Morales; Lifeng Yang; Paul Wong; Weiman Tsai; Marcela d'Alincourt Salazar; Ziv Gil; Don J Diamond; Joshua D Rabinowitz; Steven Rosen; Laleh G Melstrom
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.